Amylyx (AMLX) announced the decision to discontinue the ORION program of AMX0035 in adults living with progressive supranuclear palsy. AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24. Based on these results, the company will discontinue the Phase 2b trial and open-label extension and will not initiate the Phase 3 portion of the program. Safety data were consistent with safety data from prior studies, and AMX0035 continued to be generally well-tolerated. Amylyx continues to expect its cash runway to extend through the end of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals’ Promising Earnings Call Highlights
- Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements
- Amylyx Pharmaceuticals: Progress in Trials and Financials
- Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial